

**PB 145 of 2024**

National Health (Minimum Stockholding) Amendment Determination (No. 12) 2024

I, Eden Simon, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 20 December 2024

Eden Simon

Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments commencing 1 January 2025 2

National Health (Minimum Stockholding) Determination 2023 2

Schedule 2—Amendments commencing 1 April 2025 9

National Health (Minimum Stockholding) Determination 2023 9

Schedule 3—Amendments commencing immediately after the commencement of Schedule 2 to the *National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024* – 1 April 2025 12

National Health (Minimum Stockholding) Determination 2023 12

Schedule 4—Amendments commencing 1 June 2025 13

National Health (Minimum Stockholding) Determination 2023 13

1 Name

 (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 12) 2024*.

 (2) This instrument may also be cited as PB 145 of 2024.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 January 2025. | 1 January 2025 |
| 2. Schedule 1 | 1 January 2025. | 1 January 2025 |
| 3. Schedule 2 | 1 April 2025. | 1 April 2025 |
| 4. Schedule 3 | Immediately after the commencement of Schedule 2 to the *National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024*. | 1 April 2025 |
| 4. Schedule 4 | 1 June 2025. | 1 June 2025 |

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 January 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atenolol | Oral solution 50 mg in 10 mL, 300 mL | Oral | Atenolol‑AFT | 4 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atenolol | Oral solution 50 mg in 10 ml, 300 ml | Oral | Atenolol-AFT | (a) between 1 January 2025 and 31 May 2025—4 months stock by reference to usual PBS demand(b) after 31 May 2025—6 months stock by reference to usual PBS demand |

2 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bisoprolol | Tablet containing bisoprolol fumarate 10 mg | Oral | Cipla Bisoprolol | between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Bisoprolol | Tablet containing bisoprolol fumarate 2.5 mg | Oral | Cipla Bisoprolol | between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Bisoprolol | Tablet containing bisoprolol fumarate 5 mg | Oral | Cipla Bisoprolol | between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand |

3 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cefazolin | Powder for injection 1 g (as sodium) | Injection | Cefazolin-AFT | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cefazolin | Powder for injection 1 g (as sodium) | Injection | Cefazolin-AFT | 300,000 packs of a pack quantity of 5 |

4 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Celecoxib | Capsule 100 mg | Oral | NOUMED CELECOXIB | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Celecoxib | Capsule 200 mg | Oral | NOUMED CELECOXIB | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

5 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Duloxetine | Capsule 30 mg (as hydrochloride) | Oral | Cymbalta | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Duloxetine | Capsule 60 mg (as hydrochloride) | Oral | Cymbalta | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

6 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Prozac 20 | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

7 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | Genteal | between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | In a Wink Moisturising | between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand |

8 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lamotrigine | Tablet 100 mg | Oral | NOUMED LAMOTRIGINE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Lamotrigine | Tablet 200 mg | Oral | NOUMED LAMOTRIGINE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Lamotrigine | Tablet 25 mg | Oral | NOUMED LAMOTRIGINE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Lamotrigine | Tablet 50 mg | Oral | NOUMED LAMOTRIGINE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Lansoprazole | Capsule 30 mg | Oral | NOUMED LANSOPRAZOLE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

9 Schedule 1 (table item dealing with the drug Methoxyflurane, column number 4)

Omit “Penthrox”, substitute “Penthrox (Combination Pack)”.

10 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nortriptyline | Tablet 10 mg (as hydrochloride) | Oral | NortriTABS 10 mg | between 1 October 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Nortriptyline | Tablet 25 mg (as hydrochloride) | Oral | NortriTABS 25 mg | between 1 October 2024 and 31 December 2024—0 months stock by reference to usual demand |

11 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Phenoxymethylpenicillin | Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL | Oral | Phenoxymethylpenicillin-AFT | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |

12 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 150 mg | Oral | NOUMED PREGABALIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Pregabalin | Capsule 25 mg | Oral | NOUMED PREGABALIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Pregabalin | Capsule 300 mg | Oral | NOUMED PREGABALIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Pregabalin | Capsule 75 mg | Oral | NOUMED PREGABALIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

13 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ramipril | Tablet 1.25 mg | Oral | Tryzan Tabs 1.25 | (a) between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand(b) after 31 December 2023—3 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ramipril | Tablet 1.25 mg | Oral | Ramipril Viatris | (a) between 1 January 2025 and 28 February 2025—3 months stock by reference to usual demand of Tryzan Tabs 1.25(b) after 28 February 2025—3 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 1.25 added together |

14 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ramipril | Tablet 1.25 mg | Oral | Ramipril Viatris | (a) between 1 January 2025 and 28 February 2025—3 months stock by reference to usual demand of Tryzan Tabs 1.25(b) after 28 February 2025—3 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 1.25 added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ramipril | Tablet 10 mg | Oral | Ramipril Viatris | after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 10 added together |
| Ramipril | Tablet 2.5 mg | Oral | Ramipril Viatris | after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 2.5 added together |
| Ramipril | Tablet 5 mg | Oral | Ramipril Viatris | after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 5 added together |

15 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sertraline | Tablet 100 mg (as hydrochloride) | Oral | NOUMED SERTRALINE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Sertraline | Tablet 50 mg (as hydrochloride) | Oral | NOUMED SERTRALINE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

16 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Simvastatin | Tablet 10 mg | Oral | NOUMED SIMVASTATIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Simvastatin | Tablet 20 mg | Oral | NOUMED SIMVASTATIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Simvastatin | Tablet 40 mg | Oral | NOUMED SIMVASTATIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

17 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Telmisartan | Tablet 80 mg | Oral | NOUMED TELMISARTAN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

18 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Tenofovir ARX | 4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Viread | between 1 January 2025 and 31 March 2025—2 months stock by reference to usual demand |

Schedule 2—Amendments commencing 1 April 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Abacavir with lamivudine | Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg | Oral | Abacavir/Lamivudine Viatris | after 31 December 2024—4 months stock by reference to usual demand of both Abacavir/Lamivudine Viatris and Abacavir/Lamivudine Mylan added together |
| Acamprosate | Tablet (enteric coated) containing acamprosate calcium 333 mg | Oral | Acamprosate Viatris | after 30 July 2024—4 months stock by reference to usual demand of both Acamprosate Viatris and Acamprosate Mylan added together  |

2 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ceftriaxone | Powder for injection 1 g (as sodium) | Injection | Ceftriaxone Viatris | after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ceftriaxone | Powder for injection 1 g (as sodium) | Injection | Ceftriaxone Viatris | 6 months stock by reference to usual demand |

3 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Dosulepin | Capsule containing dosulepin hydrochloride 25 mg | Oral | Dosulepin Viatris | after 31 May 2024—6 months stock by reference to usual demand of both Dosulepin Viatris and Dosulepin Mylan added together |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Dosulepin | Capsule containing dosulepin hydrochloride 25 mg | Oral | Dosulepin Viatris | 6 months stock by reference to usual demand |

4 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entecavir | Tablet 0.5 mg (as monohydrate) | Oral | Entecavir Viatris | after 30 September 2024—4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together |

5 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | after 31 December 2024—4 months stock by reference to usual demand of both Esomeprazole Viatris and Esomeprazole Mylan added together |
| Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | after 31 December 2024—4 months stock by reference to usual demand of both Esomeprazole Viatris and Esomeprazole Mylan added together |

6 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nevirapine | Tablet 200 mg | Oral | Nevirapine Viatris | after 30 November 2024— 4 months stock by reference to usual demand of both Nevirapine Viatris and Nevirapine Alphapharm added together |

7 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Oxycodone Viatris | after 28 February 2024—6 months stock by reference to usual demand of both Oxycodone Viatris and Oxycodone Mylan added together |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Oxycodone Viatris | 6 months stock by reference to usual demand |

8 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg | Oral | Tenofovir Disoproxil Emtricitabine Viatris 300/200 | after 30 April 2024—4 months stock by reference to usual demand of both Tenofovir Disoproxil Emtricitabine Viatris 300/200 and Tenofovir Disoproxil Emtricitabine Mylan 300/200 added together |

9 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tobramycin | Injection 80 mg in 2 mL | Injection | Tobramycin Viatris | 4 months stock by reference to usual demand of both Tobramycin Viatris and Tobramycin Mylan added together |

10 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Trimethoprim | Tablet 300 mg | Oral | Trimethoprim Viatris | after 30 April 2024—6 months stock by reference to usual demand of both Trimethoprim Viatris and Trimethoprim Mylan added together |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Trimethoprim | Tablet 300 mg | Oral | Trimethoprim Viatris | 6 months stock by reference to usual demand |

Schedule 3—Amendments commencing immediately after the commencement of Schedule 2 to the *National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024* – 1 April 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atropine | Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL | Injection | Atropine Injection (Pfizer) | 6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atropine | Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL | Injection | Atropine Injection (Bridgewest) | (a) between 1 April 2025 and 30 September 2025—6 months stock by reference to usual PBS demand of Atropine Injection (Pfizer)(b) between 1 October 2025 and 31 March 2026—6 months stock by reference to usual PBS demand of both Atropine Injection (Pfizer) and Atropine Injection (Bridgewest) added together(c) after 31 March 2026—6 months stock by reference to usual PBS demand |

Schedule 4—Amendments commencing 1 June 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Escitalopram | Tablet 20 mg (as oxalate) | Oral | APX‑Escitalopram | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Estradiol and estradiol with norethisterone | Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate | Transdermal | Estalis sequi 50/140 | 6 months stock by reference to usual PBS demand |
| Estradiol with norethisterone | Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 | Transdermal | Estalis continuous 50/140 | 6 months stock by reference to usual PBS demand |